New hope for kids with tough neuroblastoma: oral drug trial begins
NCT ID NCT00295919
First seen Apr 22, 2026 · Last updated Jun 22, 2026 · Updated 9 times
Summary
This early-stage trial tested an oral powder form of the drug fenretinide (called LXS) in 80 children whose neuroblastoma had returned or resisted standard treatment. The main goals were to find the safest dose and understand side effects. Some patients also received ketoconazole to see if it boosted the drug's levels in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus
Atlanta, Georgia, 30342, United States
-
C.S. Mott Children's Hospital at University of Michigan Medical Center
Ann Arbor, Michigan, 48109-0286, United States
-
Children's Hospital Boston
Boston, Massachusetts, 02115, United States
-
Children's Hospital and Regional Medical Center - Seattle
Seattle, Washington, 98105, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104-4318, United States
-
Childrens Hospital Los Angeles
Los Angeles, California, 90027-0700, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229-3039, United States
-
Cook Children's Medical Center - Fort Worth
Fort Worth, Texas, 76104, United States
-
Lucile Packard Children's Hospital at Stanford University Medical Center
Palo Alto, California, 94304, United States
-
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94143, United States
-
University of Chicago Comer Children's Hospital
Chicago, Illinois, 60637, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fenretinide LXS oral powder
What this could lead to
If successful, this could point toward a new treatment option for children with neuroblastoma that has come back or not responded to standard therapy.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, not yet on effectiveness. The drug may not shrink tumors or improve survival, and side effects could be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.